Literature DB >> 7004806

Single-dose captopril administration in DOCA/salt rats: reduction of hypotensive effect by indomethacin.

I Miyamori, M J Brown, C T Dollery.   

Abstract

The effect of an oral angiotensin I converting enzyme inhibitor, SQ 14225 (Captopril) on blood pressure and plasma renin activity (PRA) was studied in deoxycorticosterone-salt (DOCA/salt) hypertensive rats. Intraperitoneal (ip) injection of captopril (1 mg/kg) produced a significant fall in systolic blood pressure (23.4 +/- 5.0 mm Hg, p < 0.001) whereas no significant change in blood pressure occurred in control rats. Indomethacin (IDM) (2.5 mg/kg ip) pretreatment significantly (p < 0.01) attenuated the hypotensive action of captopril in DOCA/salt rats. PRA was markedly suppressed in DOCA/salt rats (0.3 +/- 0.1 ng/ml/hr) when compared with the normotensive controls (4.4 +/- 2.2 ng/ml/hr, p < 0.001) at baseline. Captopril induced a significant rise in PRA in both groups of rats. These responses were not significantly altered by IDM pretreatment. The hypotensive effect of captopril in the DOCA/salt model may be mediated by prostaglandins since their synthesis is inhibited by indomethacin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7004806     DOI: 10.3109/10641968009037152

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 0148-3927            Impact factor:   1.749


  3 in total

Review 1.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

2.  Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat.

Authors:  D Bradshaw; P H Franz; A L Sugden
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

3.  Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.

Authors:  J R Cockcroft; P J Chowienczyk; S E Brett; N Bender; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.